Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.31 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | PPARD | Q03181 | 1/20 | 0.30 |
| ▸ | PPARA | Q07869 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL362670 | 0.88 | MAPT (0.31) | MAPTS1PR4HPGDSMN1; SMN2LMNA | |
| SCHEMBL10353221 | 0.88 | PPARD (0.30) | PPARDPPARA | |
| SCHEMBL10352725 | 0.86 | CYP19A1 (0.33) | MAPTHPGDSMN1; SMN2LMNANPSR1 | |
| SCHEMBL10353095 | 0.85 | S1PR4 (0.31) | MAPTS1PR4SMN1; SMN2HSPB1HTT | |
| SCHEMBL369212 | 0.84 | UGT1A1 (0.34) | S1PR4 | |
| SCHEMBL10279996 | 0.78 | MAOB (0.32) | PPARDPPARA | |
| SCHEMBL10353081 | 0.76 | CYP3A4 (0.31) | MAPTSMN1; SMN2 | |
| SCHEMBL361578 | 0.75 | PPARD (0.31) | PPARDPPARA | |
| SCHEMBL10356028 | 0.75 | PPARD (0.31) | PPARDPPARA | |
| SCHEMBL10279805 | 0.74 | UGT1A1 (0.38) | PPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637523-B2 | Compounds for the reduction of beta-amyloid production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-01-28 | — | — | US | disclosed |
| US-20120184565-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2012-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184565-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | APP, BACE1, IAPP | MAPT 14/4885S1PR4 3809/4885HPGD 793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.